Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) issued an announcement. SIM0610, a new bispecific antibody conjugate drug (BSAdc) candidate developed independently by the Group, has obtained a drug clinical trial approval notice issued by the China National Drug Administration to conduct clinical trials on patients with locally advanced/metastatic solid tumors.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) issued an announcement. SIM0610, a new bispecific antibody conjugate drug (BSAdc) candidate developed independently by the Group, has obtained a drug clinical trial approval notice issued by the China National Drug Administration to conduct clinical trials on patients with locally advanced/metastatic solid tumors.